|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACSM2B |
Gene summary for ACSM2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACSM2B | Gene ID | 348158 |
| Gene name | acyl-CoA synthetase medium chain family member 2B | |
| Gene Alias | ACSM2 | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q68CK6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 348158 | ACSM2B | NAFLD1 | Human | Liver | NAFLD | 9.11e-20 | 1.71e+00 | -0.04 |
| 348158 | ACSM2B | S41 | Human | Liver | Cirrhotic | 1.27e-02 | 4.96e-01 | -0.0343 |
| 348158 | ACSM2B | S43 | Human | Liver | Cirrhotic | 9.19e-08 | -2.79e-01 | -0.0187 |
| 348158 | ACSM2B | HCC1_Meng | Human | Liver | HCC | 2.89e-55 | -2.93e-01 | 0.0246 |
| 348158 | ACSM2B | HCC2_Meng | Human | Liver | HCC | 4.30e-12 | -3.94e-01 | 0.0107 |
| 348158 | ACSM2B | cirrhotic1 | Human | Liver | Cirrhotic | 1.43e-11 | -2.98e-01 | 0.0202 |
| 348158 | ACSM2B | cirrhotic2 | Human | Liver | Cirrhotic | 2.58e-12 | -3.40e-01 | 0.0201 |
| 348158 | ACSM2B | cirrhotic3 | Human | Liver | Cirrhotic | 1.08e-04 | -3.40e-01 | 0.0215 |
| 348158 | ACSM2B | HCC1 | Human | Liver | HCC | 2.08e-35 | 4.98e+00 | 0.5336 |
| 348158 | ACSM2B | HCC2 | Human | Liver | HCC | 3.98e-16 | 3.23e+00 | 0.5341 |
| 348158 | ACSM2B | HCC5 | Human | Liver | HCC | 7.94e-04 | 2.08e+00 | 0.4932 |
| 348158 | ACSM2B | Pt13.a | Human | Liver | HCC | 9.42e-12 | -1.07e-01 | 0.021 |
| 348158 | ACSM2B | Pt13.b | Human | Liver | HCC | 1.28e-32 | 2.52e-02 | 0.0251 |
| 348158 | ACSM2B | Pt13.c | Human | Liver | HCC | 1.61e-02 | -3.94e-01 | 0.0076 |
| 348158 | ACSM2B | Pt14.a | Human | Liver | HCC | 1.81e-03 | -1.53e-01 | 0.0169 |
| 348158 | ACSM2B | Pt14.b | Human | Liver | HCC | 6.72e-09 | 2.60e-01 | 0.018 |
| 348158 | ACSM2B | Pt14.d | Human | Liver | HCC | 1.96e-09 | -1.17e-01 | 0.0143 |
| 348158 | ACSM2B | S016 | Human | Liver | HCC | 1.67e-03 | -3.60e-01 | 0.2243 |
| 348158 | ACSM2B | S028 | Human | Liver | HCC | 3.13e-07 | 5.12e-01 | 0.2503 |
| 348158 | ACSM2B | S029 | Human | Liver | HCC | 3.50e-04 | 5.78e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
| GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
| GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
| GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
| GO:00092596 | Liver | NAFLD | ribonucleotide metabolic process | 72/1882 | 385/18723 | 1.51e-07 | 1.09e-05 | 72 |
| GO:00196936 | Liver | NAFLD | ribose phosphate metabolic process | 73/1882 | 396/18723 | 2.23e-07 | 1.53e-05 | 73 |
| GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
| GO:00723303 | Liver | NAFLD | monocarboxylic acid biosynthetic process | 46/1882 | 214/18723 | 5.06e-07 | 3.07e-05 | 46 |
| GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
| GO:00725217 | Liver | NAFLD | purine-containing compound metabolic process | 74/1882 | 416/18723 | 7.73e-07 | 4.27e-05 | 74 |
| GO:00091507 | Liver | NAFLD | purine ribonucleotide metabolic process | 67/1882 | 368/18723 | 1.10e-06 | 5.44e-05 | 67 |
| GO:00061637 | Liver | NAFLD | purine nucleotide metabolic process | 70/1882 | 396/18723 | 1.93e-06 | 8.23e-05 | 70 |
| GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
| GO:00338653 | Liver | NAFLD | nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
| GO:00338753 | Liver | NAFLD | ribonucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
| GO:00340323 | Liver | NAFLD | purine nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
| GO:00714663 | Liver | NAFLD | cellular response to xenobiotic stimulus | 33/1882 | 177/18723 | 3.54e-04 | 5.36e-03 | 33 |
| GO:0006637 | Liver | NAFLD | acyl-CoA metabolic process | 21/1882 | 96/18723 | 4.72e-04 | 6.74e-03 | 21 |
| GO:0035383 | Liver | NAFLD | thioester metabolic process | 21/1882 | 96/18723 | 4.72e-04 | 6.74e-03 | 21 |
| GO:00068054 | Liver | NAFLD | xenobiotic metabolic process | 22/1882 | 111/18723 | 1.42e-03 | 1.58e-02 | 22 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00650 | Liver | NAFLD | Butanoate metabolism | 11/1043 | 27/8465 | 1.88e-04 | 3.62e-03 | 2.92e-03 | 11 |
| hsa006501 | Liver | NAFLD | Butanoate metabolism | 11/1043 | 27/8465 | 1.88e-04 | 3.62e-03 | 2.92e-03 | 11 |
| hsa006502 | Liver | Cirrhotic | Butanoate metabolism | 15/2530 | 27/8465 | 4.71e-03 | 1.74e-02 | 1.07e-02 | 15 |
| hsa006503 | Liver | Cirrhotic | Butanoate metabolism | 15/2530 | 27/8465 | 4.71e-03 | 1.74e-02 | 1.07e-02 | 15 |
| hsa006504 | Liver | HCC | Butanoate metabolism | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
| hsa006505 | Liver | HCC | Butanoate metabolism | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACSM2B | SNV | Missense_Mutation | c.35C>A | p.Thr12Asn | p.T12N | Q68CK6 | protein_coding | tolerated(0.14) | benign(0.157) | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| ACSM2B | SNV | Missense_Mutation | rs769565102 | c.707C>T | p.Ser236Leu | p.S236L | Q68CK6 | protein_coding | tolerated(0.12) | benign(0.055) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ACSM2B | SNV | Missense_Mutation | novel | c.1707N>C | p.Lys569Asn | p.K569N | Q68CK6 | protein_coding | tolerated(0.07) | benign(0.039) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| ACSM2B | SNV | Missense_Mutation | c.1633G>C | p.Glu545Gln | p.E545Q | Q68CK6 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACSM2B | SNV | Missense_Mutation | novel | c.196N>C | p.Ser66Arg | p.S66R | Q68CK6 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ACSM2B | SNV | Missense_Mutation | c.1550N>G | p.Ser517Cys | p.S517C | Q68CK6 | protein_coding | deleterious(0.01) | possibly_damaging(0.652) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACSM2B | SNV | Missense_Mutation | c.1247N>T | p.Pro416Leu | p.P416L | Q68CK6 | protein_coding | deleterious(0) | benign(0.172) | TCGA-AA-A01S-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ACSM2B | SNV | Missense_Mutation | c.424N>C | p.Ser142Pro | p.S142P | Q68CK6 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ACSM2B | SNV | Missense_Mutation | novel | c.660N>G | p.Phe220Leu | p.F220L | Q68CK6 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
| ACSM2B | SNV | Missense_Mutation | c.719N>C | p.Leu240Pro | p.L240P | Q68CK6 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |